AT-104

N/A

Report date: 2023/05/05 16:59:15

NME

Base Information

Drug NameAT-104

Drug Alias NameAT-104

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitorsPhosphatidylinositol 3 kinase gamma inhibitors

TargetsPhosphatidylinositol 3 kinase deltaPhosphatidylinositol-4,5-Bisphosphate 3 kinase gamma

Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous

Inactive IndicationsN/A

ATC CodeN/A